Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Receivables (2016 - 2025)

Historic Receivables for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $579.3 million.

  • Surgery Partners' Receivables rose 670.47% to $579.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579.3 million, marking a year-over-year increase of 670.47%. This contributed to the annual value of $579.1 million for FY2024, which is 1666.0% up from last year.
  • Latest data reveals that Surgery Partners reported Receivables of $579.3 million as of Q3 2025, which was up 670.47% from $563.1 million recorded in Q2 2025.
  • Surgery Partners' 5-year Receivables high stood at $579.3 million for Q3 2025, and its period low was $367.0 million during Q1 2021.
  • For the 5-year period, Surgery Partners' Receivables averaged around $472.8 million, with its median value being $456.3 million (2022).
  • Its Receivables has fluctuated over the past 5 years, first surged by 2058.54% in 2021, then surged by 606.69% in 2022.
  • Surgery Partners' Receivables (Quarter) stood at $430.2 million in 2021, then increased by 6.07% to $456.3 million in 2022, then increased by 8.79% to $496.4 million in 2023, then increased by 16.66% to $579.1 million in 2024, then increased by 0.03% to $579.3 million in 2025.
  • Its Receivables was $579.3 million in Q3 2025, compared to $563.1 million in Q2 2025 and $570.6 million in Q1 2025.